Abstract
Realization of part of clinical trial called: Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (PF-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.
